Botulinum toxin (Dysport®) treatment of hip adductor spasticity in multiple sclerosis: A prospective, randomised, double blind, placebo controlled, dose ranging study

Journal of Neurology Neurosurgery and Psychiatry

Volumn 68, Issue 6, 2000, Pages 707-712

  Hyman, N ^a   Glickman, S ^g   Sayer, A ^h   Richardson, A ⁱ   Dott, C ⁱ   Barnes, M ^b   Bhakta, B ^c   Cozens, A ^c   Bakheit, M ^d   Kreczy Kleedorfer, B ^e   Poewe, W ^e,f   Wissel, J ^e,f   Bain, P ^g  

^a RADCLIFFE INFIRMARY   (United Kingdom)

^b Hunters Moor Regional Rehabilitation Centre   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^e Universitatsklinik fur Neurochirurgie Innsbruck   (Austria)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g CHARING CROSS HOSPITAL   (United Kingdom)

^h Royal Hospital for Neurodisability   (United Kingdom)

ⁱ IPSEN   (France)

Author keywords

Botulinum toxin; Dose range; Multiple sclerosis; Spasticity

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; PLACEBO;

ADULT; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; FEMALE; HEADACHE; HIP; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE CONTRACTION; MUSCLE HYPERTONIA; MUSCLE TONE; MUSCLE WEAKNESS; PAIN; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPASTICITY; URINARY TRACT INFECTION;

ADULT; BOTULINUM TOXIN TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HIP; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; NEUROLOGIC EXAMINATION; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0034067174     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.68.6.707     Document Type: Article

References (11)

1. Elston JS. The management of blepharospasm and hemifacial spasm. J Neurol 1992;239:5-8.
2. Blackie JD, Lees AJ. Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry 1990; 53:640-3.
3. Brans JWM, Lindeboom R, Snoek JW, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomised, double-blind controlled trial. Neurology 1996;46:1066-72.
4. Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. J Neurol Neurosurg Psychiatry 1998;64:13-7.
5. Das TK, Park DM. Effect of treatment with botulinum toxin on spasticity. Postgrad Med J 1989;65:208-10.
6. Yoshimura DM, Aminoff MJ, Olney RK. Botulinum toxin therapy for limb dystonias. Neurology 1992;42:627-30.
7. Hesse S, Friedrich H, Domasch C, et al. Botulinum toxin therapy for upper limb flexor spasticity: preliminary results. J Rehabilitation Sci 1992;5:98-101.
8. Mémim B, Pollak P, Hommel M, et al. Traitement de la spasticité par la toxine botulique. Rev Neurol (Paris) 1992; 148:212-4.
9. Snow BJ, Tsui JKC, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: a double blind study. Ann Neurol 1990;28:512-5.
10. Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998;64:6-12.
11. Delagi EF, Perotto A, Lazzetti J, et al. Anatomic guide for the electromyographer the limbs, 2nd ed. Springfield Illinois: Thomas, 1980;164-9.